Date: Tuesday 10 Jan 2012
TJX COS: Goldman Sachs downgrades to neutral from buy, price target of $72.
No recent information was found.
| For Biotech, a Tax Break Spells Hope | 10-Dec-2008 | New York Times |
| Celgene to buy Pharmion | 19-Nov-2007 | LA Times |
| Celgene to Acquire Pharmion | 19-Nov-2007 | New York Times |
| LAW NOT ON SIDE OF AMERITECH HACKER | 23-Apr-2001 | Chicago Tribune |
| Celgene Buys Rival to Get Access to Cancer Drugs | 07-Dec-2009 | Intl Herald Tribune |
| Market movers | 04-Jan-2008 | Chicago Tribune |
| Dow closes below 13,000 amid credit worries | 20-Nov-2007 | Wall Street Journal |
| Celgene to acquire Pharmion | 19-Nov-2007 | Intl Herald Tribune |
| Pfizer takes its medicine after cholesterol disa... | 05-Dec-2006 | The Independent |
| Currency | US Dollars |
| Share Price | $ 68.90 |
| Change Today | $ -1.01 |
| % Change | -1.44 % |
| 52 Week High | $80.29 |
| 52 Week Low | $51.85 |
| Volume | 2,611,439 |
| Shares Issued | 440.50m |
| Market Cap | $30,350m |
| Beta | 0.68 |
| RiskGrade | 108 |
| Strong Buy | 21 |
| Buy | 2 |
| Neutral | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 30 |

| Time | Volume / Share Price |
| 16:00 | 583 @ $68.90 |
| 16:00 | 182 @ $68.90 |
| 16:00 | 1,698 @ $68.90 |
| 16:00 | 1,152 @ $68.90 |
| 16:00 | 166 @ $68.90 |
You are here: research